NVIGEN

MOUNTAIN VIEW, CA · Founded 2011 · CIK 0001524709 · Medtech · Private

Automated liquid biopsy test using proprietary magnetic nanoparticles to detect circulating tumor DNA mutations in plasma for treatment monitoring

nvigen.com →
Grants
$2.3M
2 awards
Sector median: 1
Raised
$1.1M
2 Form D · Mar 2014
150 months since last filing
Contracts
$2.7M
3 awards · Health and Human S
#182 of 4531 in medtech
Patents
22
8 granted · 14 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$1,000,000
Private capital raisedForm D · SEC$1,116,749
Federal contractDepartment of Health and Human Services · Igf::ot::igf SBIR Phase I Topic 353: Ctdna Diagnostic Enabled By Magnetic Automation Assays$275,261
Federal contractDepartment of Health and Human Services · Topic 353: Highly Accurate Low Cost Ctdna Diagnostics With Magnetic Nanoparticle Enabled Automated Sample Prep - Moonshot$1,999,962
Federal contractDepartment of Health and Human Services · SBIR Topic 403: Highly Accurate Single Cell Sequencing With Spatial Resolution Enabled By Nanogenomics For Cancer Research$455,000
Federal grant · SBIR/STTRFederal contract · USAspendingForm D · SEC

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
179CELLSIGHT TECHNOLOGIES, INC.$2.8M—
180MAXQ RESEARCH LLC$2.8M—
181SIBTECH, INC.$2.8M—
182NVIGEN$2.7M$1.1M
183LUMOSTECH, INC.$2.7M—
184Sword Health$2.6M—
185PACT & HEALTH LLC$2.6M—

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 4 related persons
  • Aihua FuDirector · Executive Officer · Promoter
  • Xiangdong JinExecutive Officer
  • Guoliang YuDirector
  • Guo Liang YuDirector

Patents

USPTO · 8 granted of 22

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.